Alicia Mozzachio
FDA investigator
Appears on 2 documents from 2017 to 2018, mostly at sites in South Korea. Most often cites production record review (21 CFR 211.192).
- 2
- Documents on file
- 2.5
- Observations per 483
- 2017
- First seen
- 2018
- Most recent
What they cite most
From 3 observations- 21 CFR 211.192Production record review1
- 21 CFR 211.22Responsibilities of quality control unit1
- 21 CFR 211.56Sanitation1
Activity by year
2017: 1, 2018: 1
Where
South Korea 2
Often inspects with
Is Alicia Mozzachio coming to your site?
Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.
Ask about any investigator in Claude or ChatGPT with the AI connector.
Inspection history
2 documents, newest first| Date | Firm | Location | Observations | Open |
|---|---|---|---|---|
| 2018-03-14 | 483 Samsung Biologics Co., Ltd.Mar 14, 2018 · Incheon, South Korea | Incheon, South Korea | 2 | |
| 2017-11-17 | 483 Daewoong Pharmaceutical Co., Ltd. 35-14, Jeyakgongdan 4-Gil, Hyangnam-EupNov 17, 2017 · Hwaseong-Si, South Korea | Hwaseong-Si, South Korea | 3 |
About this profile
What does Alicia Mozzachio inspect?
Alicia Mozzachio appears on 2 documents on file covering 2 sites, mostly in South Korea.
What do they cite most often?
21 CFR 211.192 (production record review), followed by 21 CFR 211.22 and 21 CFR 211.56.
Can I read the observations?
Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.
How current is this profile?
The most recent document on file for Alicia Mozzachio is dated Mar 14, 2018.